Ras pathway activation in malignant mesothelioma

Journal of Thoracic Oncology

Volumn 2, Issue 9, 2007, Pages 789-795

  Patel, Manish R ^a   Jacobson, Blake A ^a   De, Arpita ^a   Frizelle, Sandra P ^b   Janne, Pasi ^a   Thumma, Saritha C ^a   Whitson, Brian A ^a   Farassati, Faris ^a   Kratzke, Robert A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cap dependent; Eukaryotic initiation factor 4E; Mesothelioma; Ras; Translation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GUANOSINE TRIPHOSPHATE; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTHRACENES; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MESOTHELIOMA; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 34548391771     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31811f3aab     Document Type: Article

References (28)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
2. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-1989.
3. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat 2000;62:51-62.
4. Papp T, Schipper H, Pemsel H, et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001;18:425-433.
5. Olut A, Firat P, Ertugrul D, Gungen Y, Emri S. Ras oncoprotein expression in erionite- and asbestos-induced Turkish malignant pleural mesothelioma patients - a pilot study. Respir Med 2001;95:697-698.
6. Ni Z, Liu Y, Keshava N, Zhou G, Whong W, Ong T. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 2000;468:87-92.
7. Metcalf RA, Welsh JA, Bennett WP, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992;52:2610-2615.
8. Cesario A, Catassi A, Festi L, et al. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. Clin Cancer Res 2005;11:2026-2037.
9. Hoang CD, D'Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004;125:1843-1852.
10. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000;36:522-528.
11. Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000;5:591-596.
12. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998;124:291-296.
13. Phelps R, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch Cell Line Data Base. J Cell Biochem Suppl 1996;24:32-91.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
15. Jacobson BA, Alter MD, Kratzke MG, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 2006;66:4256-4262.
16. Usami N, Fukui T, Kondo M, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006;97:387-394.
17. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-275.
18. Wilson KF, Cerione RA. Signal transduction and post-transcriptional gene expression. Biol Chem 2000;381:357-365.
19. Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-563.
20. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-3199.
21. Sabourin CL, Wang QS, Ralston SL, et al. Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. Exp Lung Res 1998;24:499-521.
22. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003;20:265-273.
23. Mukohara T, Civiello G, Davis IJ, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005;11:8122-8130.
24. Pass HI, Robinson BW, Testa JR, Carbone M. Emerging translational therapies for mesothelioma. Chest 1999;116:455S-460S.
25. Toyooka S, Carbone M, Toyooka KO, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4344.
26. Dohner H, Pilz T, Fischer K, et al. Molecular cytogenetic analysis of RB-1 deletions in chronic B-cell leukemias. Leuk Lymphoma 1994;16:97-103.
27. Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005;68:500-510.
28. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 1998;157:1616-1622.